| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DIRS1; FNDC6; I20RB; IL-20R-beta; IL-20R2 |
| Entrez GeneID | 53833; |
| WB Predicted band size | 35kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human IL20RB. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IL20RB抗体的参考文献示例(注：以下为假设性示例，建议通过学术数据库验证最新文献)：
---
1. **文献名称**: *Targeting IL20RB with a monoclonal antibody inhibits angiogenesis in inflammatory diseases*
**作者**: Zhang Y, et al.
**摘要**: 本研究开发了一种靶向IL20RB的单克隆抗体，通过阻断IL-20信号通路，显著抑制了银屑病和类风湿性关节炎模型中的病理性血管生成和炎症反应。
2. **文献名称**: *IL20RB blockade attenuates liver fibrosis via suppressing hepatic stellate cell activation*
**作者**: Kim S, et al.
**摘要**: 抗IL20RB抗体通过抑制肝星状细胞的活化和胶原沉积，在小鼠肝纤维化模型中展现出治疗潜力，揭示了其在慢性肝病中的临床应用价值。
3. **文献名称**: *A humanized anti-IL20RB antibody modulates Th17 responses in autoimmune encephalomyelitis*
**作者**: Wang X, et al.
**摘要**: 人源化IL20RB抗体通过调节Th17细胞分化和IL-17分泌，在多发性硬化症动物模型中有效减轻神经炎症和脱髓鞘病变。
4. **文献名称**: *IL20RB-specific antibody enhances antitumor immunity in triple-negative breast cancer*
**作者**: Patel R, et al.
**摘要**: 抗IL20RB抗体联合免疫检查点抑制剂，在三阴性乳腺癌模型中协同增强CD8+ T细胞浸润，显著抑制肿瘤生长并延长生存期。
---
建议通过 **PubMed** 或 **Google Scholar** 搜索关键词“IL20RB antibody therapeutic”或“IL20RB blockade”获取最新研究。
The IL20RB antibody targets the interleukin-20 receptor beta subunit (IL20RB), a key component of the heterodimeric receptors for cytokines IL-19. IL-20. and IL-24 within the IL-10 family. IL20RB pairs with IL20RA or IL6ST (gp130) to mediate signaling through JAK/STAT pathways, influencing inflammatory responses, epidermal homeostasis, and tissue remodeling. Dysregulation of IL20RB signaling is implicated in autoimmune and inflammatory disorders, such as psoriasis, rheumatoid arthritis, and certain cancers, where aberrant cytokine activity drives pathogenic inflammation or tumor progression.
IL20RB antibodies are primarily used as research tools to investigate receptor-ligand interactions, signaling mechanisms, and cellular responses in disease models. Therapeutically, they hold potential for blocking pro-inflammatory cytokine signaling, offering a strategy to mitigate chronic inflammation or cancer-related angiogenesis. Preclinical studies have explored neutralizing antibodies to inhibit IL-20 subfamily cytokines, showing promise in reducing skin inflammation in psoriasis-like models. Challenges include optimizing specificity to avoid off-target effects and ensuring tissue-selective modulation to preserve physiological roles of IL20RB in epithelial repair. Current research focuses on refining antibody design for clinical translation, with some candidates in early-stage development for autoimmune and oncological indications.
×
